Arca
Skip to content

Dermatitis

Drug research and approvals for dermatitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 234 studies of dermatitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 213 drug trials for it since 2013, FDA has 0 approved and 2 open orphan designations naming it, and the EU has 8 authorised medicines for it.

  • Recruiting worldwide: 234
  • Trials authorized in Canada: 213
  • FDA orphan approvals: 0
  • EU medicines: 8

Recruiting Now

Newest start dates first, of 234 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

9 approved, 10 in phase 3, 11 in phase 2, 12 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Dexamethasone, Gentamicin, Zinc oxide, Betamethasone acetate, Triamcinolone acetonide, Methylprednisolone hemisuccinate, Methylprednisolone acetate, Dimethicone, Aluminum chlorohydrate

Dupilumab
Phase 3 Interleukin-4 receptor subunit alpha antagonist
Cetirizine
Phase 3 Histamine H1 receptor antagonist
Levocetirizine
Phase 3 Histamine H1 receptor antagonist
Butenafine
Phase 3 Squalene monooxygenase inhibitor
Ketoconazole
Phase 3 Cytochrome P450 51 inhibitor
Pimecrolimus
Phase 3 FK506-binding protein 1A inhibitor
Clemastine
Phase 3 Histamine H1 receptor antagonist
Desloratadine
Phase 3 Histamine H1 receptor antagonist
Bepotastine
Phase 3 Histamine H1 receptor antagonist
Ketotifen
Phase 3 Histamine H1 receptor antagonist
Acitretin
Phase 2 Retinoid receptor agonist
Doxycycline anhydrous
Phase 2 Matrix metalloproteinase 7 inhibitor
Roflumilast
Phase 2 Phosphodiesterase 4 inhibitor
Sulfamethoxazole
Phase 2 Bacterial dihydropteroate synthase inhibitor
Trimethoprim
Phase 2 Bacterial dihydrofolate reductase inhibitor
Cephalexin anhydrous
Phase 2 Bacterial penicillin-binding protein inhibitor
Apremilast
Phase 2 Phosphodiesterase 4 inhibitor
Crisaborole
Phase 2 Phosphodiesterase 4 inhibitor
Risankizumab
Phase 2 Interleukin-23 inhibitor
Gusacitinib
Phase 2 Janus Kinase (JAK) inhibitor
Ruxolitinib
Phase 1 Tyrosine-protein kinase JAK1 inhibitor
Olive oil
Phase 1
Adriforant
Phase 1 Histamine H4 receptor antagonist
Etokimab
Phase 1 Interleukin-33 binding agent
Udifitimod
Phase 1
Ompekimig
Phase 1

Showing the 30 furthest along of 33 in trials.

How Its Trials Ended

1,674 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 372 whose ending is known, 48% met their primary endpoint, 4% missed it and 48% stopped early.

  • Completed, result not reported81449%
  • Ongoing33520%
  • Met its primary endpoint17911%
  • Status unknown1539%
  • Stopped: other or unclear905%
  • Stopped: lack of efficacy292%
  • Stopped: enrollment or feasibility292%
  • Stopped: sponsor or business decision221%
  • Missed its primary endpoint141%
  • Stopped: funding91%

Trials Authorized in Canada

The 10 newest of 213; search them all in Canada trials
Sep 16, 2026A phase 3, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin (nktr-358) monotherapy…Rezpegaldesleukin (NKTR-358)Nektar TherapeuticsPending
Sep 10, 2026A randomized, double-blind, parallel group, placebo-controlled phase 3 combination therapy study to investigate the efficacy & safety oftilrekimig in adult &…Tilrekimig (PF-07275315)PfizerOngoing
Sep 2, 2026A phase 3, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin (nktr-358) monotherapy…Rezpegaldesleukin (NKTR-358)Nektar TherapeuticsOngoing
Sep 2, 2026A phase 3, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin (nktr-358) monotherapy…Rezpegaldesleukin (NKTR-358)Nektar TherapeuticsOngoing
Aug 12, 2026A phase 2, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy, safety, and pharmacokinetics of multiple subcutaneous…TRIV-573Triveni Bio, Inc.Pending
Jun 18, 2026A phase 2 multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and preliminary efficacy of soquelitinib in…Soquelitinib (CPI-818)Corvus Pharmaceuticals IncOngoing
Jun 8, 2026A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of env-294 in adult…ENV-294Enveda Therapeutics IncPending
Jun 4, 2026A long-term extension study to evaluate the safety and efficacy of subcutaneous img-007 in participants of a previous img-007 moderate-to-severe atopic…IMG-007Inmagene LLCOngoing
Apr 9, 2026A phase 2b, multicenter, randomized, doubleblind, placebo-controlled study to evaluate the efficacy and safety of camoteskimab in adults with…Camoteskimab (APL-9109)Apollo Therapeutics, LimitedOngoing
Dec 30, 2025A pilot study designed to evaluate the use of pch-415 in aiding in the diagnosis of allergic contact dermatitisPCH-415 diagnostic patch (pre-filled diagnostic patch test system)Evme, Inc.Ongoing

FDA Orphan Designations

Approved first, then open designations, newest first
Oct 24, 1991MetronidazoleTreatment of perioral dermatitis.Galderma Laboratories, Inc.Designated
Sep 10, 1990SulfapyridineTreatment of dermatitis herpetiformis.Jacobus Pharmaceutical CompanyDesignated

Medicines Authorised in the EU

Newest first
Feb 12, 2025NemluvioNemolizumabGalderma InternationalEMA ↗
Sep 19, 2024AnzupgoDelgocitinibLEO Pharma A/SEMA ↗
Nov 16, 2023EbglyssLebrikizumabAlmirall, S.A.EMA ↗
Apr 19, 2023OpzeluraRuxolitinibIncyte Biosciences Distribution B.V.EMA ↗
Dec 9, 2021CibinqoAbrocitinibPfizer Europe MA EEIGEMA ↗
Jun 17, 2021AdtralzaTralokinumabLEO Pharma A/SEMA ↗
Sep 26, 2017DupixentDupilumabSanofi Winthrop IndustrieEMA ↗
Feb 27, 2002ProtopicTacrolimusLEO Pharma A/SEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.